Key Takeaways
- • Coller Capital raised a £500 million single-asset continuation fund for Pharmacy2U, one of the largest GP-led secondary transactions in European health-tech, with Akin serving as legal counsel to the lead investor.
- • The bespoke continuation vehicle provides liquidity to existing investors while enabling Pharmacy2U, a U.K. online pharmacy leader, to pursue its next growth phase with G Square Healthcare Private Equity LLP as the managing GP.
- • The transaction structure includes reinvestment from G Square, existing shareholders, and a syndicate of institutional investors alongside Coller Capital's lead position, demonstrating strong confidence in the platform's trajectory.
- • Akin's advisory team, led by investment management partners Daniel Quinn and Qasam Mahmood, navigated tax, antitrust, and international competition considerations across the continuation fund structure.
Summary
Coller Capital has secured a £500 million continuation fund focused exclusively on Pharmacy2U, the U.K. online pharmacy platform, marking one of the most significant GP-led secondary transactions in the European health-tech sector. The transaction was structured as a bespoke single-asset vehicle managed by G Square Healthcare Private Equity LLP and advised by Akin, a leading international law firm with over 1,000 lawyers across major global offices.
The continuation fund model addresses a common challenge in growth-stage private equity: providing exit liquidity to early-stage investors while preserving operational momentum and enabling further value creation. In this case, the structure allows existing shareholders and G Square to reinvest alongside Coller Capital's lead commitment, signaling continued confidence in Pharmacy2U's market position and growth potential. The inclusion of a broader syndicate of institutional investors further validates the investment thesis and distributes risk across multiple limited partners.
Pharmacy2U's online pharmacy model, operating in a regulated but increasingly digital-forward healthcare market, represents an attractive consolidation and growth opportunity. The continuation fund provides capital for expansion, technology development, and potential add-on acquisitions while offering exit flexibility for early investors who may have held positions since the platform's founding or earlier growth rounds.
Akin's advisory engagement encompassed complex multi-jurisdictional considerations. The legal team, led by partners Daniel Quinn and Qasam Mahmood with support from tax counsel Mohammed Natha and antitrust partner Davina Garrod, addressed investment management structuring, tax optimization, and regulatory compliance across international markets. This scope reflects the cross-border nature of U.K.-based healthcare tech platforms and the regulatory scrutiny applicable to pharmacy operations and data handling.
For institutional investors, the transaction demonstrates continued appetite for health-tech secondaries with defensive characteristics—online pharmacy combines recurring customer relationships, regulatory barriers to entry, and demographic tailwinds from aging populations and digital adoption in healthcare.
The continuation fund model addresses a common challenge in growth-stage private equity: providing exit liquidity to early-stage investors while preserving operational momentum and enabling further value creation. In this case, the structure allows existing shareholders and G Square to reinvest alongside Coller Capital's lead commitment, signaling continued confidence in Pharmacy2U's market position and growth potential. The inclusion of a broader syndicate of institutional investors further validates the investment thesis and distributes risk across multiple limited partners.
Pharmacy2U's online pharmacy model, operating in a regulated but increasingly digital-forward healthcare market, represents an attractive consolidation and growth opportunity. The continuation fund provides capital for expansion, technology development, and potential add-on acquisitions while offering exit flexibility for early investors who may have held positions since the platform's founding or earlier growth rounds.
Akin's advisory engagement encompassed complex multi-jurisdictional considerations. The legal team, led by partners Daniel Quinn and Qasam Mahmood with support from tax counsel Mohammed Natha and antitrust partner Davina Garrod, addressed investment management structuring, tax optimization, and regulatory compliance across international markets. This scope reflects the cross-border nature of U.K.-based healthcare tech platforms and the regulatory scrutiny applicable to pharmacy operations and data handling.
For institutional investors, the transaction demonstrates continued appetite for health-tech secondaries with defensive characteristics—online pharmacy combines recurring customer relationships, regulatory barriers to entry, and demographic tailwinds from aging populations and digital adoption in healthcare.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.